Prajakta Adsul, MBBS, PhD
The findings, published today in JAMA Internal Medicine, revealed screening use in FQHCs was 45.4% for breast cancer, 51% for cervical cancer and 40.2% for colorectal cancer, compared to cancer screening rates in the general American population of 78.2%, 82.9% and 72.3%, respectively.
“FQHCs provide high-quality primary care to underserved communities in the US, which are disproportionately comprised of racial and ethnic minorities, people without health insurance, and those living below the poverty level,” said study author Jane Montealegre, PhD, associate professor of Behavioral Science at MD Anderson. “These findings highlight an urgent need to focus on scaling up evidence-based screenings in these populations to mitigate cancer disparities.”
The U.S. Preventive Services Task Force (USPSTF) offers guidance for the general population to get screened for breast, cervical and colorectal cancer based on age and family history. However, screening use remains suboptimal in many marginalized populations. About 30 million people in the U.S. who might not otherwise have access to medical services currently use FQHCs.
The study, led by postdoctoral fellow Trisha Amboree, PhD, examined screening information from the Health Center Program Uniform Data System from 1,364 FQHCs between January 1 and December 31, 2020. To understand screening in the general population, researchers evaluated data from the Behavioral Risk Factor Surveillance System, which includes the use of preventive health services for non-institutionalized U.S. adults over the age of 18, during the same time period.
Researchers found cancer screening use in FQHCs varied widely across states. Certain states, such as Maine and New Hampshire, achieved screening rates over 60% and others fell below 35%, including Utah, Wyoming and Alabama. Additionally, the study revealed underscreened populations served by FQHCs in specific states contributed to a large proportion of America’s overall underscreened population. Experts attribute these differences, in part, to the variability of state screening programs and policies around healthcare funding.
“FQHCs face financial constraints and staff turnover while trying to provide care in a fragmented health system. Implementing clinical preventive services such as cancer screenings will require additional support,” said corresponding author Prajakta Adsul, MBBS, PhD, assistant professor of Internal Medicine at UNM. “With investments in implementation research in FQHCs, there is potential to mitigate screening-related disparities in medically underserved populations.”
Limitations of the study include self-reporting in the datasets and potential effects from the COVID-19 pandemic.
The research was supported by the National Institutes of Health (R01MD013715, R01CA232888, R01CA256660). A full list of collaborating authors and their disclosures can be found here.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
About the University of New Mexico
The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. Its more than 136 board-certified oncology specialty physicians include cancer surgeons in every specialty, adult and pediatric hematologists/medical oncologists, gynecologic oncologists and radiation oncologists. They, along with more than 600 other cancer healthcare professionals (nurses, pharmacists, nutritionists, navigators, psychologists and social workers), provide treatment to 65% of New Mexico’s cancer patients from all across the state and partner with community health systems statewide to provide cancer care closer to home. Since 2015, they have published nearly 1000 manuscripts, and promoting economic development, they filed 136 new patents and launched 10 new biotechnology start-up companies. The physicians, scientists and staff have provided education and training experiences to more than 500 high school, undergraduate, graduate and postdoctoral fellowship students in cancer research and cancer health care delivery.
RSS